Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial.

J Intensive Med · 2025 · PMC11763862 · PMID 39872839

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The distribution of the WHO ordinal scale classification showed a trend that SIR1-365 increased the percentage of patients with ambulatory mild disease and decreased the percentages of hospitalized patients with moderate or severe disease, compared with placebo ( Figure 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.